Drug Trial Radar · NCT06456346
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Jul 16, 2024
Primary completion
Sep 28, 2027
Study completion Mar 24, 2028
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated. Its primary objective is to compare bomedemstat to hydroxyurea with respect to durable clinicohematologic response (DCHR). The primary hypothesis is that bomedemstat is superior to hydroxyurea with respect to DCHR.
Conditions
- Essential Thrombocythemia
Interventions
BomedemstatDrug
Oral capsule
HydroxyureaDrug
Oral capsule
Bomedemstat placeboDrug
Oral capsule placebo
Hydroxyurea placeboDrug
Oral capsule placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Durable Clinicohematologic Response (DCHR) RateTime frame: Up to approximately 52 weeks
Locations
171 sites in 23 countries. Site status is shown where the registry gives one.
Palo Verde Cancer Specialists ( Site 0052)
Glendale, Arizona
Los Angeles Cancer Network ( Site 0025)
Glendale, California
Stanford Cancer Center ( Site 0024)
Palo Alto, California
Exempla Lutheran Medical Center ( Site 0014)
Golden, Colorado
Yale University School of Medicine ( Site 0051)
New Haven, Connecticut
Parkview Research Center at Parkview Regional Medical Center ( Site 0006)
Fort Wayne, Indiana
University of Michigan ( Site 0003)
Ann Arbor, Michigan
Optum Care Cancer Center ( Site 0053)
Las Vegas, Nevada
Levine Cancer Institute ( Site 0009)
Charlotte, North Carolina
Duke University Health System (DUHS) ( Site 0012)
Durham, North Carolina
Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 0013)
Winston-Salem, North Carolina
The Ohio State University Wexner Medical Center ( Site 0028)
Columbus, Ohio
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8005)
Eugene, Oregon
Oregon Health & Science University ( Site 0018)
Portland, Oregon
TriStar Bone Marrow ( Site 7000)
Nashville, Tennessee
Texas Oncology - West Texas ( Site 8003)
Amarillo, Texas
Texas Oncology - DFW ( Site 8006)
Dallas, Texas
University of Texas MD Anderson Cancer Center ( Site 0026)
Houston, Texas
University of Texas Health Science Center at San Antonio ( Site 0021)
San Antonio, Texas
Texas Oncology - Gulf Coast ( Site 8008)
Webster, Texas
University of Virginia ( Site 0020)
Charlottesville, Virginia
VCU Health Adult Outpatient Pavillion ( Site 0008)
Richmond, Virginia
Clínica de Nefrología, Urología y Enfermedades Cardiovasculares ( Site 0105)
Santa Fe, Argentina
Hospital Universitario Austral ( Site 0101)
Pilar, Buenos Aires, Argentina
Hospital Italiano de Buenos Aires ( Site 0102)
ABB, Buenos Aires F.D., Argentina
C.I.C.E. 9 de Julio ( Site 0104)
San Miguel de Tucumán, Tucumán Province, Argentina
Westmead Hospital ( Site 0201)
Westmead, New South Wales, Australia
Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 0203)
Adelaide, South Australia, Australia
Monash Health-Haematology Research ( Site 0202)
Clayton, Victoria, Australia
Austin Health-Cancer Clinical Trials Centre ( Site 0206)
Heidelberg, Victoria, Australia
Royal Perth Hospital-Haematology ( Site 0204)
Perth, Western Australia, Australia
Ordensklinikum Linz GmbH Elisabethinen ( Site 0562)
Linz, Upper Austria, Austria
Arthur J.E. Child Comprehensive Cancer Centre ( Site 0038)
Calgary, Alberta, Canada
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0037)
Greenfield Park, Quebec, Canada
Biocenter ( Site 0149)
Concepción, Biobio, Chile
IC La Serena Research ( Site 0150)
La Serena, Coquimbo Region, Chile
FALP-UIDO ( Site 0148)
Santiago, Region M. de Santiago, Chile
Clínica Inmunocel ( Site 0147)
Santiago, Region M. de Santiago, Chile
Clínica Alemana de Santiago ( Site 0143)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 0142)
Santiago, Region M. de Santiago, Chile
Showing 40 of 171 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.